QIAGEN Pre-Tax Profit Margin 2010-2023 | QGEN
Current and historical pre-tax profit margin for QIAGEN (QGEN) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. QIAGEN pre-tax profit margin for the three months ending March 31, 2023 was .
QIAGEN Pre-Tax Profit Margin Historical Data |
Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
2023-03-31 |
$2.00B |
$0.43B |
21.36% |
2022-12-31 |
$2.14B |
$0.51B |
24.00% |
2022-09-30 |
$2.23B |
$0.57B |
25.74% |
2022-06-30 |
$2.26B |
$0.63B |
27.78% |
2022-03-31 |
$2.31B |
$0.66B |
28.63% |
2021-12-31 |
$2.25B |
$0.63B |
27.77% |
2021-09-30 |
$2.24B |
$0.72B |
31.96% |
2021-06-30 |
$2.19B |
$0.59B |
27.09% |
2021-03-31 |
$2.07B |
$0.55B |
26.73% |
2020-12-31 |
$1.87B |
$0.44B |
23.48% |
2020-09-30 |
$1.71B |
$0.25B |
14.72% |
2020-06-30 |
$1.61B |
$-0.00B |
-0.19% |
2020-03-31 |
$1.55B |
$-0.06B |
-3.87% |
2019-12-31 |
$1.53B |
$-0.08B |
-5.11% |
2019-09-30 |
$1.52B |
$-0.08B |
-5.21% |
2019-06-30 |
$1.51B |
$0.22B |
14.55% |
2019-03-31 |
$1.51B |
$0.21B |
14.20% |
2018-12-31 |
$1.50B |
$0.23B |
14.98% |
2018-09-30 |
$1.50B |
$0.19B |
12.77% |
2018-06-30 |
$1.48B |
$0.17B |
11.54% |
2018-03-31 |
$1.45B |
$0.14B |
9.42% |
2017-12-31 |
$1.42B |
$0.11B |
8.04% |
2017-09-30 |
$1.39B |
$0.07B |
4.76% |
2017-06-30 |
$1.36B |
$0.05B |
3.82% |
2017-03-31 |
$1.35B |
$0.06B |
4.67% |
2016-12-31 |
$1.34B |
$0.06B |
4.26% |
2016-09-30 |
$1.32B |
$0.12B |
9.17% |
2016-06-30 |
$1.30B |
$0.12B |
9.34% |
2016-03-31 |
$1.28B |
$0.13B |
9.91% |
2015-12-31 |
$1.28B |
$0.14B |
10.62% |
2015-09-30 |
$1.29B |
$0.10B |
7.82% |
2015-06-30 |
$1.31B |
$0.10B |
7.62% |
2015-03-31 |
$1.33B |
$0.11B |
8.30% |
2014-12-31 |
$1.34B |
$0.12B |
8.85% |
2014-09-30 |
$1.35B |
$0.14B |
10.04% |
2014-06-30 |
$1.33B |
$0.13B |
9.62% |
2014-03-31 |
$1.32B |
$0.04B |
3.19% |
2013-12-31 |
$1.30B |
$0.04B |
2.84% |
2013-09-30 |
$1.29B |
$0.05B |
3.49% |
2013-06-30 |
$1.27B |
$0.05B |
3.86% |
2013-03-31 |
$1.26B |
$0.14B |
10.70% |
2012-12-31 |
$1.25B |
$0.15B |
11.56% |
2012-09-30 |
$1.24B |
$0.08B |
6.77% |
2012-06-30 |
$1.23B |
$0.09B |
7.59% |
2012-03-31 |
$1.20B |
$0.09B |
7.83% |
2011-12-31 |
$1.17B |
$0.10B |
8.21% |
2011-09-30 |
$1.12B |
$0.16B |
14.54% |
2011-06-30 |
$1.11B |
$0.17B |
15.10% |
2011-03-31 |
$1.09B |
$0.17B |
15.36% |
2010-12-31 |
$1.09B |
$0.17B |
15.92% |
2010-09-30 |
$1.09B |
$0.18B |
16.24% |
2010-06-30 |
$1.08B |
$0.18B |
16.64% |
2010-03-31 |
$1.05B |
$0.18B |
17.09% |
2009-12-31 |
$1.01B |
$0.17B |
17.03% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$10.347B |
$2.142B |
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|